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Draft Minutes of the Meeting 
The Department of Health and Human Services (HHS) and the Centers for Disease Control 
and Prevention (CDC) convened a meeting of the Advisory Committee on Childhood Lead 
Poisoning Prevention (ACCLPP). The proceedings were held on September 18-19, 2007 at 
the Radisson Plaza Hotel in Minneapolis, Minnesota . 
. 4IJlenln.· .....rO~ \ "'~ 
Dr. George Rhoads, Chair of ACCLPP, called the meeting to order at 8:45 a.m. on 
September 18, 2007 and welcomed the attendees to the proceedings. 
Dr. Mary Jean Brown, Executive Secretary of ACCLPP and Chief of the CDC Lead 
Poisoning Prevention Branch (LPPB), announced that voting members with a real or 
perceived conflict of interest related to any item on the September 18-19, 2007 ACCLPP 
agenda would be responsible for identifying these issues and recusing themselves from 
voting on these topics or participating in these discussions. 
Dr. Brown opened the floor for introductions. The list of participants is appended to the 
minutes as Attachment 1. 
Dr. Brown was pleased to introduce and summarize the achievements of an honored guest. 
Ms. Gretchen Musicant, Health Commissioner of the City of Minneapolis, has made strong 
efforts to create a public health focus on youth violence in the city. As a result of these 
activities, Minneapolis is allocating special violence prevention grants and convened a task 
force to address youth violence from a public health intervention perspective. 
Commissioner Musicant was recently awarded with a public health achievement award in 
recognition of her distinguished service to promote and protect the health of individuals, 
families and the community in Minneapolis . 
._---- _ ._-­
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Commissioner Musicant emphasized that she was honored ACCLPP selected Minneapolis 
as its meeting site. Childhood lead poisoning in general and the Healthy People 2010 goal 
of reaching all children to reduce lead poisoning in particular are extremely important issues 
throughout the city. Although Minneapolis increased the number of children tested for lead, 
the number of children identified with elevated blood lead levels (EBLLs) has decre.ased. 
Despite these efforts, however, Minneapolis reported 335 cases of EBLLs in children in 
2006. 
Commissioner Musicant described several citywide measures in which Minneapolis is 
incorporating the issue of lead to reduce its current burden. In its "Sustainability Effort," 
Minneapolis designated lead testing and 21 additional indicators to measure its status. as a 
sustainable community. The lead testing indicator includes a map of locations where 
EBLLs most frequently were detected. The report of the Sustainability Effort is available on 
the city of Minneapolis web site. 
In its "Results Minneapolis" initiative, city departments are being held accountable for lead 
and other specific indicators. Minneapolis established a new partnership with Section 8 
low-income housing because this agency conducts systematic risk assessments and makes 
referrals for remediation. Minneapolis passed a new Lead-Safe Work Practice Ordinance in 
January 2007 that requires certification for repair of any homes identified with chippin!~ and 
peeling paint. 
Lead outreach and education activities in Minneapolis include collaborative efforts with the 
Sustainable Resource Center and agencies at state and county levels. Minneapolis and its 
partners have leveraged resources from federal agencies and other sources to conduct 
innovative activities, particularly the "Leady Eddie Van" that is used to provide community 
education. 
Commissioner Musicant described one of the most significant challenges in lead that 
Minneapolis is facing at this time. Many providers are hesitant about counseling families of 
children who have positive test results for lead exposure, but are below the federal "lead 
poisoned" threshold. Minneapolis is reviewing its existing lead standards to coliaboratE~ with 
providers and families in addressing this need. Commissioner Musicant emphasized that 
the city of Minneapol;s looked forward to reviewing the guidance and recommendations 
ACCLPP provided during its meeting. 
Dr. Brown informed Commissioner Musicant that ACCLPP's clinical paper on adverse 
health effects of BLLs <10 1J9/dL would be co-published by the Morbidity and Mortality 
Weekly Report (MMWR) and Pediatrics. The city of Minneapolis particularly would find this 
information useful because the paper describes actions healthcare providers can take in 
counseling families of children with BLLs <10 IJg/dL. The paper would be available to the 
public on both the CDC and Pediatrics web sites on November 1, 2007. 
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The participants joined Dr. Brown in applauding the outstanding contributions of Dr. Helen 
Binns, the ACClPP liaison to the American Academy of Pediatrics, who served as the 
primary author of the paper over a four-year period. 
Dr. Brown covered the following areas in her update. The Consumer Product Safety 
Commission (CPSC) recalled 44 different toys or 12.2 million units from January 5­
September 5,2007 due to dangerous levels of lead. Data indicate that as much as 50% of 
recalled items are not removed from shelves and even fewer recalled items are disposed of 
once sold. 
At this time, Connecticut is the only state requiring toy manufacturers to certify that re(:alled 
toys have been disposed of as hazardous waste. CPSC's silence on this issue is extrE~mely 
important because recalled toys could be sold elsewhere or recycled and placed into new 
products. Dr. Brown raised the possibility of ACClPP addressing CPSC's silence on the 
disposal of recalled toys. 
Dr. Brown reported that lPPB took several actions in response to this public health issue. 
First, a new fact sheet was developed and posted on the CDC web site with links to CPSC 
and the National Center for Healthy Housing (NCHH). The fact sheet contains the following 
key messages to consumers. The toy should be immediately removed if parents suspect 
their child has been exposed to a toy containing lead. Most children with EBlls have no 
symptoms. A blood lead test is the only definitive method to confirm whether the child has 
an EBlL. A healthcare provider can assist the parent in deciding whether a blood lead test 
is needed and also can recommend treatment if the child has been exposed. 
Second, specific recommendations were developed for pediatric healthcare providers. 
Providers who contact lPPB requesting assistance are informed that a blood lead tesit is a 
fairly straightforward medical procedure covered by Medicaid and most private health 
insurance. Providers also are advised to perform blood lead tests in cases with extrE~mely 
anxious or persistent parents. 
Third, ASTM International develops worldwide standards and has establish~~d a 
subcommittee in response to CPSC's request to draft standard specifications for lead 
content in vinyl plastics used in children's consumer products. CDC, the U.S. 
Environmental Protection Agency (EPA), NCHH, and toy manufacturers and seller:s are 
represented on the subcommittee. 
Dr. Brown highlighted the key points of ASTM's draft standards. The language is limited to 
vinyl products that are specifically marketed to children. A threshold of 600 ppm is 
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proposed for lead in children's vinyl products. Testing methodologies that are destructive 
and laboratory-based are proposed. 
Dr. Brown conveyed that CDC and other members of the ASTM subcommittee made 
several comments in response to the draft standards. Plastics in products that are 
commonly used by children should be included in the standards along with vinyl products. 
The threshold of 600 ppm was established based on available good manufacturing 
practices and also when children's BLLs were higher in the past. Studies should be 
conducted to determine a lower level that is achievable in the current manufacturing 
environment. 
The standards should be modified with an explicit statement to clarify that lead is NOT to be 
added to plastic products commonly used by children. X-ray fluorescence should be 
investigated as an analytic method and included as an acceptable testing method if 
performed. Dr. Brown announced that ASTM would hold its next subcommittee meeting in 
October 2007 and would release the draft standards for public comment over the ne>:t few 
months. 
Dr. Brown was pleased to report that LPPB recently developed a Healthcare EffectivEmess 
Data and Information Set (HEDIS) measure for lead screening of children enrolled in 
Medicaid. HEDIS is one of the most widely used sets of healthcare performance measures 
in the United States and serves as a report card for health plans. The National Committee 
for Quality Assurance maintains HEDIS and will include 70 measures across eight domains 
of care in the 2008 HEDIS measures. 
Dr. Brown summarized the key features of the lead screening HEDIS measure. The 
description of the HEDIS measure is the percentage of Medicaid-enrolled children two years 
of age who have had ~1 blood lead tests by their second birthday. The denominator 4)f the 
HEDIS measure is children who are two years of age during the measurement year in 2008 
and who are continuously enrolled for 12 months prior to their second birthday. However, 
one gap of 30 days is permitted. 
The hybrid measure of the HEDIS measure allows health plans to report both immuni~:ation 
status and screening and also use the same sample for both measures. Dr. Brown 
confirmed that she would inform ACCLPP of any differences in blood lead testing for 
children who are continuously enrolled in Medicaid with only one 30-day gap versus 
children who have gaps in enrollment for >30 days. 
Dr. Brown emphasized that the lead screening HEDIS measure would not significantly 
increase the current cost of collecting or analyzing data. At the end of 2008, aggregate data 
would be produced on the status of children enrolled in Medicaid and their blood lead 
testing results by two years of age for the entire country. The performance of a particular 
health plan would not be known in the first year of the lead screening HEDIS measure, but 
the second year of the measure would be plan-specific. 
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Dr. Brown informed ACCLPP that in support of the lead screening HEDIS measure, LPPB 
drafted recommendations on blood lead screening of young children enrolled in Medicaid. 
LPPB's draft guidance is consistent with ACCLPP's long-standing efforts and focus 011 this 
issue since 2000. LPPB expects to publish the recommendations in the MMWR OVE!r the 
next year after the CDC clearance process is completed. 
Table 1 of LPPB's recommendations describes specific action steps for state and local 
officials to (1) update blood lead screening policies for Medicaid-enrolled children; (2) 
improve rates of blood lead screening for Medicaid-enrolled children at increased risk; and 
(3) design and implement updated surveillance and evaluation strategies. 
Table 2 of LPPB's recommendations outlines strategies for healthcare providers to provide 
blood lead screening and follow-up care. Dr. Brown confirmed that she would provide 
ACCLPP with the entire document of LPPB's draft recommendations on blood lead 
screening of young children enrolled in Medicaid. ACCLPP would be asked to review and 
submit comments on the draft recommendations in a one-month period of time. 
Dr. Brown announced that LPPB is continuing its international lead activities in Ko:sovo. 
After the war in the former Yugoslavia, refugee camps were built in the 1990s on three sites 
that are heavily contaminated with lead from smelting and other sources. The three refugee 
camps are a significant industrial concern and house -300 children. CDC became involved 
in this effort in 2005 because previous testing indicated that all of the children had BLL!) ~65 
1J9/dL and some children died as a result of receiving inappropriate forms of chelation. 
Dr. Brown summarized LPPB's key findings and recommendations based on its site vi~;its to 
the Kosovo camps. From 2005-2007, 30% of children who were tested had capillary BLLs 
~45 1J9/dL. Few if any of the children living in the camps have maintained BLLs <10 pg/dL 
for their entire childhood. 
Cesman Lug is the most highly contaminated camp and should be immediately closed. The 
situation in the Cesman Lug camp is made more critical because Roma living in Serbic:l and 
Montenegro are now moving into vacant dwellings in the camp. Dwellings that are currently 
vacant should be immediately demolished due to lead contamination and a clear and 
present fire hazard. 
The lack of data has hampered decision-making and resulted in confusion on the part of 
Roma and others as to the seriousness of the problem and the extent of environmental 
contamination. A periodic and systematic data review would provide important information 
about the quality of the children's clinical care. Perhaps as many as 90 children are 
candidates for therapy, but only 39 children reportedly have been chelated to date. The 
actual number cannot be determined at this time. 
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The United Nations Mission in Kosovo or the U.S. Agency for International Development 
should attempt to identify a donor nation that would be willing to build more lead-free 
apartment complexes. Lead exposure should be a priority for repatriation to the Homa 
Mahala. Plans should be developed for continued medical surveillance of these children 
during their repatriation to Roma Mahala. LPPB is attempting to establish a strong 
presence in Kosovo to address issues related to mining, smelting and informal smeltin~J. 
Dr. Brown informed ACCLPP that LPPB also is continuing its international lead activities in 
Peru. LPPB conducted an investigation in response to an EpiAid request in Cerro de Pasco 
where the main economic activity is lead mining. From 1996-2002, 520 children were 
tested with mean BLLs ranging from 14-37 \Jg/dL. In 2005, 85% of children 1-10 years of 
age had EBLLs. 
LPPB's site visit to Cerro de Pasco in 2007 showed EBLLs in children 1-12 years of age 
that were similar to those identified in 2005. LBBP hopes to convene an international 
conference possibly in October 2008 with the International Lead Zinc Resl~arch 
Organization, World Bank, World Health Organization (WHO) and other groups to formally 
go on record with solid international lead recommendations. 
Discussion 
Ms. Jacqueline Mosby, ACCLPP's ex-officio member for EPA, announced that EPA and 
CPSC have been discussing the development of a campaign or formal statement regarding 
the disposal of recalled toys. EPA is collaborating with its Office of Solid Waste on crE~ating 
an appropriate approach to assist parents in identifying lead-containing toys. Ms. Mosby 
confirmed that an EPA staff member with expertise in solid waste and Resource Consen/ation 
and Recovery Act regulations would attend the next interagency task force meeting to address 
this issue. 
ACCLPP commended LPPB on its diligent efforts and outstanding activities following the 
March 2007 meeting. Several members suggested actions that LPPB and ACCLPP should 
take to advance childhood lead poisoning prevention and elimination efforts. 
• 	 LPPB's guidance to providers on recalled toys should emphasize that the risk 
of lead exposure from toys would be highest in younger children with 
mouthing behaviors. Specific recommendations might minimize the number 
of unnecessary blood tests in older children. 
• 	 LPPB's lead screening HEDIS measure should contain clear guidance to 
providers on financial penalties if Medicaid rules are not completely followed. 
For example, LPPB's advice would be extremely important in determining 
whether Medicaid would pay for a child's visit in which a local Women, Infants 
and Children (WIC) clinic tested a provider's patient for lead, forwarded the 
test results to the provider, and the provider had no other reason to repe,at the 
test. 
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• 	 ACCLPP should formally address CPSC's policy of "re-gifting" children's 
jewelry, toys and other products to countries outside of the United State~; with 
less scrutiny. 
• 	 ACCLPP should develop and distribute a strong position paper with two 
clearly defined terms. First, ACCLPP should define "trace levels" of lead in 
children's products because a solid threshold has not established to date. 
CPSC's definition of an "acceptable" trace level of lead in children's jewE~lry is 
<600 ppm or 7.8 1J9/dL over a one-month period of time. Second, ACCLPP 
should define "children's products." The definition of children's products in 
legislation that was recently introduced is extremely problematic, such as 
"products intended for children ~6 years of age." 
• 	 ACCLPP should explore strategies with CPSC to establish a certific:ation 
process in which "lead-free" tags would be placed on children's toys and 
jewelry. 
• 	 ACCLPP should discuss the possibility of developing educational materials 
and providing web-based technical assistance to countries where lead­
containing products for children have been exported. The materials and 
technical assistance could be made available to Ministries of Health to assist 
in informing consumers in these countries about the dangers of recallecl toys 
and other products and the harm to children. 
In addition to ACCLPP's suggestions, Dr. Kosnett made a formal proposal for the members 
to consider. ACCLPP should recommend that international trade organizations address 
public health issues related to trade. This approach could promote the development of a 
worldwide agreement in which no country that permitted the manufacture of lead-contclining 
children's jewelry and toys or allowed significant or unacceptable amounts of lead-based 
paint in the manufacture of toys to be a part of the international trading community. 
Dr. Kosnett explained that ACCLPP's role in this effort could be to promote collegial 
educational interactions between the public health communities in the United States and 
developing countries. For example, an international conference could be held in China in 
2008 to take advantage of the tremendous amount of global attention, visitors and media 
coverage of China at that time due to the Olympics. 
The overarching purpose of the international conference would be for ACCLPP to educate 
and interact with Chinese public health officials. Overall, Dr. Kosnett's position was that the 
United States should offer its support and raise awareness of China's concerns regarding 
international trade of lead-containing products to children. 
Dr. Brown made a number of comments and clarifying statements in response to ACCLPP's 
comments, concerns and suggestions. A Imports" Task Force was recently 
established under a Presidential Executive Order. HHS is the lead agency on the task 
force, but CDC does not serve as a member. 
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Dr. Brown outlined several potential approaches for ACCLPP to take in its future direction. 
ACCLPP could issue formal recommendations to the Safe Imports Task Force due to its 
charter to advise both the HHS Secretary and CDC Director. ACCLPP could communicate 
with WHO about the importation of lead-safe products to children. Dr. Brown and the 
ACCLPP members could identify and discuss their collective contacts with health officials, 
governmental agencies, academia and other colleagues in China to determine the feasibility 
and cost of convening an international conference in China. 
Individual ACCLPP members could contact their respective Congressional representatives 
and health legislative aides on this issue as well. To assist ACCLPP in identifying its future 
direction and strategies, Dr. Brown confirmed that copies of recently introduced legislation 
on lead-containing children's products would be distributed to the voting members. 
Dr. Brown was aware of ACCLPP's strong concerns about CPSC's legal authority to "re-gift" 
or export children's jewelry, toys and other products to other countries. She informed 
ACCLPP that CPSC is a member of the Presidential Task Force on safe importation. If 
ACCLPP decided to write a letter to the HHS Secretary on this issue, this communication 
could be used as a platform to make recommendations directly to CPSC. 
Dr. Brown advised the members that rapid actions would need to be taken on the order of 
weeks to months if ACCLPP decided to communicate with the HHS Secretary on the issue 
of safe imports. She pointed out that the Presidential Executive Order only provided the 
task force with 60 days to develop a framework for safe imports. The task force's 
framework would be released for public comment and also distributed to ACCLPP. 
Actions 
ACCLPP concluded the discussion by agreeing to take action on two issues. First, a new 
workgroup would be established to draft a letter outlining ACCLPP's major concerns 
regarding the import, export and disposal of lead-containing toys and other products to 
children. After ACCLPP's review, comments, revisions and formal approval, the letter 
would be finalized and sent to the HHS Secretary. ACCLPP's cleared letter would be 
widely distributed to CPSC, WHO and other organizations. 
Based on Dr. Brown's clarification, the workgroup would not be charged with defining "trace 
levels" of lead in consumer products because this effort is under the purview of CPSC or 
other regulatory agencies rather than CDC. 
The following ACCLPP members, liaisons and ex-officios volunteered to serve on thE! new 
workgroup: Ms. Angeloni, Dr. Cory-Slechta, Dr. Gitterman, Mr. Hays, Ms. Kite, Dr. Kosnett, 
Ms. Malone, Ms. Mosby, Dr. Sandel and Dr. Stubbs-Wynn. Ms. Wendy Blumenthal, of 
LPPB, would provide staff support to the workgroup and contact the members over the next 
two weeks. During its first conference call, the workgroup would discuss strategies to most 
effectively convey ACCLPP's comments and concerns to the HHS Secretary. 
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Second, a motion was properly placed on the floor and seconded by Dr. Sandel and Ms. 
Kite, respectively, for ACCLPP to make comments on ATSM's draft standards when the 
public comment period is opened over the next few months. ACCLPP unanimously 
approved the motion. 
'i\~F CMrvre.w oI"';~ .·[~ " Chlldh()dct~"POI.Onl~g ·p,.v....on·...I'08"~ (CLPPP) 
Dr. Daniel Symonik, Program Director of the Minnesota CLPPP, reported that the 
Minnesota Department of Heath (MDOH) developed its "2010 Childhood Lead Poisoning 
Elimination Plan" to create a lead-safe state in which all children have BLLs <10 IJg/dL by 
the year 2010. The elimination plan focuses on primary prevention. The governor of 
Minnesota approved the plan in 2004, but MDOH is collaborating with partners to update 
the document. 
Dr. Symonik outlined the key components of MDOH's elimination plan. Lead poisoning 
almost always has no immediate symptoms except in severe cases. Blood testing is the 
only method to identify EBLLs. Developmental effects of lead in children are permanent. 
Prevention is a critical component in preventing EBLLs from occurring, keeping EBLLs from 
becoming higher, and reducing EBLLs as quickly as possible. 
Dr. Symonik explained that the Minnesota Blood Lead Information System was established 
by statute and authorizes four major activities. BLLs in children and adults will be 
monitored. Screening services will be provided to high-risk populations. Follow-up selVices 
will be provided for children with EBLLs. Information on primary prevention programs will 
be distributed. 
MDOH's blood lead guidelines are categorized into several distinct groups. The "screening" 
guidelines address children and pregnant women, routine screening and periodic evaluation 
based on state -specific risk factors. Assessment agencies with appropriate jurisdiction in 
Minnesota have statutory authority to visit the home and write an enforceable lead clE~anup 
order if a pregnant woman is identified with a BLL >10 IJg/dL. However, the statute does 
now allow Minnesota to gather data on pregnancy status. The "case management" 
guidelines address public health interventions based on lead levels. The guidelines were 
reissued in 2005 with a new format and additional language from CDC's <10 IJg/dL data. 
The "clinical treatment" guidelines address medical evaluation, management and follow-up 
to provide guidance to physicians. MDOH developed the guidelines in collaboration with a 
group of local physicians. The "screening guidelines" were issued in 2000 and will be 
comprehensively reviewed and updated by an expert panel to reflect current data, trends 
and rates. MDOH currently recommends universal screening in Minneapolis, St. Paul and 
the remainder of the state based on risk factors. The expert panel will be charged with 
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determining whether universal screening is still warranted in Minneapolis and St. Paul 
based on current rates. 
Dr. Symonik was pleased to announce that MDOH increased its screening rates from '1998­
2006 and nearly tripled the number of children tested over this period of time. MOOH's 
blood lead guidelines, solid efforts at the local level, and the "withhold" clause in MOOH's 
annual contract with health plans to provide public health services played a significant role 
in the success of increasing screening throughout the state. 
The withhold clause allows MDOH to pay health plans 1 % of the state contract that is 
initially withheld only if certain performance goals are met. This provision is extre!mely 
significant in terms of incentives because one health plan was not paid $3 million in one 
year for not meeting performance goals. The withhold clause also has prompted health 
plans to pursue data matching agreements with MDOH to identify positive lead test results 
for specific children. 
In terms of children with EBlls, MDOH's environmental intervention level is a single v€!nous 
test of 15 l-Ig/dL. MDOH has continued to make progress in decreasing the number of 
EBlls in children throughout the state. Despite these efforts, a fatal lead case occurred in 
Minnesota in February 2006 after a child swallowed a piece of jewelry and developed 
influenza-like symptoms. The child had a Bll of 180 l-Ig/dl based on blood lead te!sting 
and died the same day as the initial report. 
Tests revealed that the piece of jewelry swallowed by the child contained 60%-90% of lead, 
but other similar jewelry was tested and showed <0.06% of lead. MDOH coordinab:!d its 
response to the media and public with CDC, CPSC, the Minneapolis health department, and 
the governor and mayor. The case was published in the MMWR. 
Dr. Symonik described MDOH's recent studies and other activities. MDOH published a 
countryside lead prevalence study in 2005 to address the prevalence of lead in rural areas. 
From 2001-2002, 70% of all children in three counties were tested. Rural rates were found 
to be similar to national estimates. The main contributors to lead in rural areas were WIC 
status, residence in pre-1950 housing, and other risk factors established by MDOH. The 
study is available to the public on the MDOH web site. 
MDOH recently analyzed data to determine differences between WIC and refugee status as 
a risk factor for lead. WIC clinic screening was performed in three separate projects 
targeting high-risk areas. Of 2,772 persons screened, only 8 had BllS ~10 l-Ig/dl and only 
one child had an EBll >20 l-Ig/dL. Of 305 pregnant women tested in Hennepin County, 
only one had an EBlL. 
MDOH performed refugee screening with 150 children in St. Paul in 2006 to evaluate CDC's 
new guidelines. Of all screened children, 93% received a second blood test. The source of 
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lead in these children most likely was outside of the United States. MDOH plans to publish 
these data over the next year. 
For its housing-based activities, MDOH has been successful in receiving HUD lead h;:lzard 
reduction grants for lead hazard control. MDOH has used these funds for primary 
prevention to enter homes and also to educate contractors and homeowners on lead-safe 
practices. MDOH has made strong efforts to promote coordination between health and 
housing agencies. Annual resources to MDOH for lead poisoning prevention include $4 
million from HUD, $590,000 from CDC, $500,000 from a state general fund, $200,000 from 
EPA, and additional funding from private sources and nonprofit organizations. 
Mr. James Yannarelly, of the Ramsey County Department of Public Health (RCDPH) in St. 
Paul, Minnesota, provided a local perspective on housing-based activities. RCDPH is 
focusing on this issue through a number of solid partnerships with local and state age'ncies 
and private organizations. RCDPH has received a significant amount of funding sinc:e the 
early 1990s to change its secondary prevention lead program to a housing-based primary 
prevention program. Although ....87% of houses in Ramsey County have lead, a significant 
portion of the lead causes no problems due to appropriate maintenance, management and 
control. 
RCDPH has taken several actions to target primary prevention efforts to problem areas, 
such as developing strategies, collaborating with national organizations, implemEmting 
effective models, delivering benchmarks, and sharing lessons learned. RCDPH also 
partners with private contractors that implement lead-safe work practices (LSWP), adhere to 
HUD guidelines and follow CDC/ACCLPP recommendations. RCDPH performs ....2 
rehabilitation projects each week that require paint stabilization, .... 17 window replacements, 
and overnight relocation of the family to a local hotel. 
RCDPH paid for ....5 contractors to undergo a four-day supervisory course. The respective 
crews of each contractor were trained in the LSWP program. RCDPH performed a 
complete clearance process on initial projects the contractors completed following training. 
The contractors were shown their strengths and weaknesses in rehabilitation work. Overall, 
RCDPH's training resulted in positive changes in behaviors and practices among the 
contractors during rehabilitation of housing units, such as the purchase and use of HEPA 
vacuums and improved cleanup. Mr. Yannarelly commended CDC for its stronger focus on 
housing-based primary prevention. 
Dr. Patrick Parsons, of the New York State Department of Health and chair of the 
workgroup, conveyed that the workgroup includes representatives from CDC, ACCLPP and 
external groups with expertise in the subject matter. The workgroup has held three 
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conference calls to date and circulated its first draft report among the members in July 
2007. The workgroup expects to distribute the document to ACCLPP for review and 
comment in the near future. Key issues on the workgroup's agenda are outlined below: 
• 	 Current laboratory capabilities for blood lead. 
• 	 Criteria for acceptable blood lead laboratory performance in Clinical 
Laboratory Improvement Amendments (CLlA) approved proficiency tE~sting 
(PT) programs. 
• 	 The impact of more stringent criteria for PT performance based on the lise of 
reference methods by centralized laboratories and the use of the LeaciCare 
device by point-of-care laboratories. 
• 	 Misclassification of children based on laboratory errors. 
Dr. Parsons described current methods for blood lead testing. The highly complex and 
automated graphite furnace atomic absorption spectrometry (GFASS) system is one of the 
most widely used reference methods for measuring lead in blood and has a detection limit 
of 1 ~g/dL. The cost of GFASS ranges from $30,000 for a basic unit to $50,000 for a more 
robust and well-equipped unit. Anodic stripping voltammetry (ASV) is a modestly complex 
and non-automated bench-top unit that is based on electrochemistry. ASV has a detE~ction 
limit of -2-3 ~g/dL and costs $10,000-$15,000. 
Inductively coupled plasma mass spectrometry (ICP-MS) is an extremely complex and 
automated system that has a detection limit of -0.5 ~g/dL. The cost of ICP-MS ranges from 
$180,000-$250,000. The old LeadCare device is a handheld and non-automated ASV 
technology that is based on electrochemistry and is considered to be moderately complex 
under CLiA. LeadCare" is the new waived and non-automated device that has a detE~ction 
limit of -2-3 ~g/dL and costs $2,000-$3,000. However, LeadCare " will be problematic 
because the device is different than reference method technologies. Moreover, the 
performance of LeadCare " in the field has not been definitively assessed to date. 
Dr. Parsons summarized the history and current environment of regulating clinical 
laboratories in the United States. The federal government has regulated clinical 
laboratories through the Occupational Safety and Health Administration (OSHA) since the 
1970& and CLiA 'SS 1 regulations drove the standardization of laboratory 
performance across the entire spectrum of clinical laboratory medicine. At the state level, 
oversight of clinical laboratories greatly varies by state. 
Laboratory oversight is achieved through mandatory proficiency testing except when 
waived, laboratory standards and laboratory inspections. PT is used to determine 
laboratory testing performance via inter-laboratory comparisons in the United States, while 
external quality assessment schemes (EQAS) are used in Europe and elsewhere. 
PT programs in the United States and EQAS programs in Europe and Canada have 
philosophical differences. For example, laboratories in the United States that fail PT might 
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receive a letter from the regulatory agency to cease patient testing. EQAS is a voluntary 
activity and laboratories that fail this program have less serious consequences than PT 
failure in the United States. 
PT testing under CLiA '88 covers the entire spectrum of clinical laboratory medicine of three 
test events per year and five challenges or PT samples per test event. Laboratories must 
score 80% or receive four correct challenges out of five on each blood lead test eVEmt to 
earn "satisfactory" PT performance for the test event. 
For cumulative performance under CLiA '88, laboratories must maintain ~80% on at least 
two out of three blood lead test events to earn "successful" PT performance. An 
"unsuccessful" PT performance is two consecutive failures out of three. ConsequencE~s for 
unsuccessful PT performance could include a letter from a state agency or a CLiA regional 
office instructing the laboratory to investigate the source of the error or cease patient 
testing. The laboratory would need to remediate the errors and demonstrate proficiency 
before resuming patient testing. 
Requirements for unsuccessful laboratories to resume patient testing vary based on 
standards established by the accrediting agency in the region, the vigor of the local office in 
pursuing poor performance, and the level of oversight in each state. However, one of the 
most important components in laboratory performance is capacity for rapid turnaround of 
results to ensure that laboratories are quickly made aware of problems. 
Several factors play an important role in deciding the total error level that is acceptable for 
blood lead testing, such as clinical and public health needs, method performance, 
laboratory capabilities and capacity, and the most effective tools for a specific purpos'9. In 
addition to these factors, data were published in 2000 to inform the decision-making 
process. 
The study compared procedures for evaluating laboratory performance in EQAS for lead in 
blood and aluminum in serum. The study also demonstrated the need for common quality 
specifications. The study was based on a proposed approach that used clinical inputs to 
establish targets for analytical imprecision, bias and the total allowable error level. Quality 
specifications were efaborated as well. 
The study suggested that the CLiA '88 recommendations for ±4 or ±10% of the target 
concentration, whichever would be greater, could be used as a quality specification. 
However, the study recommended a revision of ±3 or ±10%. Current blood lead 
performance criteria include the CLiA '88 standard of ±4, the OSHA standard of ±6, and the 
average standard in European countries of ±3. 
Dr. Parsons reported that the workgroup discussed potential impacts on U.S. laboratories if 
the current performance limits for blood lead testing were changed. In this effort, the 
workgroup evaluated data from two PT programs. The New York State (NYS) Department 
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of Health PT Program for Blood Lead is a state regulatory program that is mandatory for all 
clinical laboratories serving NYS. Of 108 laboratories that serve NYS, 49% use GFASS, 
19% use bench-top ASV, 21 % use ICP-MS, and 11 % use the LeadCare analyzer. 
The Wisconsin State Laboratory of Hygiene PT Program for Blood Lead is a voluntary 
program that is supported by federal grants and does not require a fee to participants. Of 
469 laboratories that serve Wisconsin, 61% use the LeadCare analyzer. 
The standard deviation between laboratories showed that ICP-MS was the best technology 
of the four with BLLs of 6 and 11 1J9/dL. An analysis of data showed that NYS PT reference 
methods, excluding LeadCare laboratories, were fairly stable up to 20 1J9/dL depending on 
whether the criteria were ±3 or ±4. Performance decreased to below 90% with BLLs :30-38 
IJg/dL regardless of whether criteria were ±1-3. The analysis showed that this change 
would have consequences for laboratories at BLLS 10-30 IJg/dL. 
An analysis of NYS LeadCare laboratories showed that these laboratories had significant 
difficulties in maintaining proficiency >20%, particularly at criteria of ±1 1J9/dL. The amilysis 
showed that any change in criteria would impact laboratories that use the LeaciCare 
tech nology. 
An analysis of data showed that Wisconsin PT refereed methods, excluding LeaciCare 
laboratories, began to decrease in performance with criteria of ±2 at BLLs >15 1J9/dL. The 
analysis showed that these laboratories would be impacted by a change in performance 
criteria. An analysis of Wisconsin LeadCare laboratories showed decreased performance 
with criteria of ±3. 
Federal regulations contain language stating that in cases with a lack of consensus on a 
particular PT sample, samples would be ungradable and would be scored with 100%. The 
NYS PT Program has avoided this provision by using a select group of 15 reference 
laboratories to establish target values. The Wisconsin PT Program is unable to grade its 
LeadCare laboratories against established referee target values because the LeadCare 
technology is extremely sensitive to the age of blood and can only be used with fresh whole 
blood. The practice of the Wisconsin PT Program in freezing blood before an event causes 
a d;screpancy in the target value. 
Data were reviewed from the NYS PT Program to determine the impact of changing blood 
lead performance limits on laboratory permit status. The analysis showed that with current 
criteria of ±4/±10%, 10%-15% of laboratories would be at risk of failure and <6% would be 
unsuccessful and fail PT. With criteria of ±3/±10%, 15% of laboratories would be at risk of 
failure and -6% would be unsuccessful and fail PT. The minimal difference between these 
two results demonstrates that a change to criteria of ±3/±10% could be implemented 
without serious unintended consequences for laboratory capacity. 
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With criteria of ±2/±10%, 25% of laboratories would be at risk of failure and nearly 10% 
would be unsuccessful and fail PT. This finding indicates that caution should be taken in 
recommending a change to these criteria due to the strong potential for undesirable and 
unintended consequences. With criteria of ±1/±10%,33% of laboratories would be at risk of 
failure and 15% would be unsuccessful and fail PT. 
Based on these findings, Dr. Parsons supported an incremental approach to improving 
laboratory performance by changing criteria to ±3/±10% initially and ±2/±10% in the future. 
An initial change in criteria to ±2/±10% could result in serious consequences due to the 
decertification of large commercial laboratories. 
Dr. Parsons noted that one of the workgroup members analyzed data from nine commercial 
laboratories to determine the impact of changing blood lead PT criteria on internal quality 
assurance practices. The two control levels used in the analysis were BLLs of 9 and 25 
j.lg/dL. The study demonstrated the need to analyze differences in methodologies to meet 
these standards. 
Dr. Parsons highlighted the workgroup's key findings to date. Better laboratory 
performance is needed, particularly at low blood lead concentrations. A change in the 
current performance standard should not result in unintended consequences in the future. 
Laboratories have the capacity to enhance performance. 
Dr. Parsons emphasized that all of the workgroup members have not agreed on the 
following proposed approach. A phased approach is recommended to tighten the standard 
one step at a time. Implementation of a more stringent standard of ±3/±10% at this time is 
desirable, feasible and consistent with current European standards. The impact Clf this 
change would be revisited in 12-24 months to determine whether laboratory perfomlance 
improved as a result of the first change. Consideration would then be given to adopting a 
new standard of ±2/±10%at that time. 
The workgroup also identified a number of problems in changing the current performance 
criteria for laboratories. Efforts to modify the current federal regulation will be extn~mely 
difficult. The old LeadCare system might be unable to meet new standards. ThE~ new 
LeadCare system ts waived is not subject to federal PT oversight. Some might 
demand satisfactory PT performance. Users should be educated on the limitations of 
various technologies. 
Overall, Dr. Parsons emphasized the need for ACCLPP to issue an explicit charge to the 
workgroup in terms of making specific recommendations on error limits. ACCLPP also 
could instruct the workgroup to elfpand its charge to provide guidance on handling 
LeadCare for screening. 
Ms. Blumenthal announced that the workgroup reviewed preliminary BLL sensitivity and 
specificity data from National Health and Nutrition Examination Survey (NHANES) statistical 
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analyses. The workgroup performed this data review due to its interest in identifying cases 
where children were misclassified as "false-positive" or "false-negative." The workgroup 
took this approach because of the need to make evidence-based recommendations that 
reflect a public health need to lower the current performance criteria. 
The sensitivity and specificity analyses were based on simulations of various EBLL 
prevalence rates and the following assumptions. BLLs in NHANES represented thE~ true 
BLL for a child. BLLs generated for the analysis included a given fixed error level that was 
added to or subtracted from the "true" value. The error value was randomly added or 
subtracted. The ratio of a high to low error level was -50/50 and might not be accunate in 
terms of actual laboratory experience. 
In the analysis, 100 iterations were run and each iteration differed in terms of assigning 
error levels. The limitations of the analysis included a simulation design that would result in 
a hypothesis of "potential" outcomes versus "actual" laboratory performance. The sensitivity 
and specificity values used in the analysis were mean values. 
Ms. Blumenthal outlined key findings of the analysis. The percentage of children who were 
truly positive based on blood lead testing and would be appropriately offered intervEmtion 
was significantly impacted as the error level tightened. The error level dramatically 
increased from 34 with criteria of ±3 to -51 with criteria of ±4. 
The expected numbers of false-positives in a hypothetical population of 100,000 children 
were significantly impacted when criteria were tightened from ±4 to ±3. False-negatives 
were similarly impacted with a population prevalence of 10%. These findings caused ()ne of 
the workgroup members to express concern about a rapid shift from the current crite!ria of 
±4 to ±2. A quick change could drive more laboratories to consider using the LeadCare II 
instrument that would not be subject to PT standards. 
Several ACCLPP members made suggestions to assist the Blood Lead Laboratory 
Workgroup in conducting future activities. 
• 	 CDC should include language in future program announcements that requires 
states to perform PT testing. 
• 	 ACCLPP should recommend decoupling performance limits for blood lead 
testing from current regulations. With this approach, a non-regulatory E!Xpert 
panel could issue guidance on the standards that would be relevant to public 
health needs and consistent with existing laboratory capacity. 
• 	 ACCLPP should strongly promote voluntary standards in additi()n to 
mandatory standards. For example, a laboratory that exceeds mandatory 
standards could advertise its performance as a "gold star" lead laboratory. 
• 	 ACCLPP should expand the workgroup's charge to advise clinical 
laboratories to standardize or generalize interpretations that are routinely 
provided with blood lead tests. 
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Dr. Rhoads suggested that ACCLPP could formally address its comments by writing a letter 
to the appropriate entity and emphasizing three key points. First, the current performance 
standard should be changed from ±4 to ±3 as soon as practicable. Second, ACCLPP 
recognizes the need for a change in laboratory performance criteria to ±2 at this time, but 
this change should be implemented over the next two years if possible. Third, ACCLPP 
supports decoupling current standards from federal regulations into a more flE~xible 
administrative process. 
The following motion was properly placed on the floor and seconded by Dr. Sandel and Dr. 
Gardner, respectively. ACCLPP should expand the charge of the Blood Lead Laboratory 
Workgroup to analyze reference methods and LeadCare issues and make 
recommendations in this regard. This guidance will have tremendous implications for the 
practice and detection of BLLs. ACCLPP unanimously approved the motion. 
Dr. Parsons made several comments in response to ACCLPP's discussion. The work!~roup 
would support Dr. Rhoads' suggestion for ACCLPP to write a letter on the need to change 
current laboratory performance criteria. In response to Dr. Sandel's motion that ACCLPP 
unanimously approved, a representative of the LeadCare manufacturer would need to be 
invited to join the workgroup. This approach would make it more likely that the 
manufacturer would support and endorse the workgroup's recommendations. 
Dr. Brown reported on actions that have been taken to shift LPPB's sole focus on childhood 
lead poisoning prevention to a more holistic housing approach. CDC is making strong 
efforts to complete LPPB's entire transformation over the next year. The Healthy People 
2010 goal for childhood lead pOisoning is to prevent BLLs ~10 1J9/dL as a public health 
problem. 
The Healthy People 2010 goal related to housing is to reduce the number of housing units 
with moderate or severe physical problems by 50%. To achieve this goal, the number of 
housing units with moderate or severe problems would need to be decreased from -6,500 
to -3,200 million units. Data collected by the American Housing Survey from 1995·-2005 
showed minimal improvement over this time in the number of occupied housing units in the 
United States with "moderate or severe" or "moderate and severe" physical problems. 
CDC is developing a "Healthy Housing Framework for Action" in preparation of a "Surgeon 
General's Call to Action" to organize general contractors, architects, urban plannen; and 
other groups in the United States around this public health issue. A clear distinction will be 
made between "housing" and "home" in this initiative. A "healthy house" is defined as one 
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that is sited, designed, built, maintained and renovated in ways that support the health of its 
occupants. LPPB is focusing on the interaction between the actual structure and residEmts. 
Dr. Brown summarized the five guiding principles of the healthy housing framework for 
action. One, public awareness will be increased by creating a national dialogue on healthy 
housing and promoting health literacy about housing. A national dialogue will improve 
public understanding of the relationship between housing and health. Health literacy will be 
increased in many contexts and settings, including individual families, academia, 
professionals, and stakeholders involved in the housing industry and community planning. 
Greater knowledge about key health issues will provide persons with capacity to make 
informed, evidence-based and compassionate housing decisions. 
Two, actions will be taken to ensure that all Americans have access to healthy, safE~ and 
affordable housing. Housing design and construction can hamper ease of mobility within a 
home and interfere with reasonable access to important features of the house, suc:h as 
toilets, shelving in cupboards, and closets for elderly and disabled persons. Of all U.S. 
families, 13 million spend >50% of their income on housing and might not be able to 
purchase health care, medicines or adequate food. Living in a neighborhood with a 
concentrated poverty level increases emotional stress and exposure to intentional injury. 
Three, the physical and mental health of individuals will be promoted through evid~~nce­
based healthy housing interventions. Lowering hot water temperature, installing window 
guards and implementing other safety measures result in less pediatric burns and falls. The 
risk of death is decreased by 40%-50% when a fire occurs in a home with a working smoke 
alarm. 
Lead paint abatement reduces the likelihood that more children will be lead poisoned in 
homes where children have been poisoned in the past. Radon testing and carbon 
monoxide monitors reduce deaths in the home. Integrated pest management and use of 
the least toxic baits and insecticides result in fewer insect pests and less reliance on 
chemical pesticides. Involuntary exposure to secondhand tobacco smoke can be prevEmted 
by making homes, workplaces and public places smoke-free. 
Four, investments will be made in research to advance current knowledge of strategies for 
healthy housing and improve physical and mental health. Additional housing factor!; that 
can harm or promote and protect the health of individuals will be identified. Understanding 
of causal sequences of events leading to specific injuries will be strengthened. The 
physiologic pathway that links the housing environment and mental health will be described. 
Understanding of building practices that improve the health of residents will be enhanced. 
Scientific and analytic methods that are available to researchers who conduct formative 
studies in this area will be improved. 
Five, investments will be made in research that enhances understanding of the long-term 
economic benefits of healthy housing. Additional studies are needed to quantify the relative 
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benefits and cost-savings of modern construction practices, such as increasing the width of 
stairs and traction on floor surfaces, improving home lighting, and installing handrails. 
Investments also should be made in energy conservation, green construction and 
renovation practices, and similar improvements that result in improved health of residents, 
cost-savings and other benefits. 
Dr. Brown noted that reuniting public health and housing policy is not a new concept and is 
simply a matter of restoring a once vital link. This activity is feasible because the course is 
increasingly clear and well mapped. Moreover, key participants have been identified and 
initial steps have been taken. Strengthening and widening these efforts is an urgent m.atter. 
Dr. Brown described CDC's ongoing and future activities to support the effort of reuniting 
public health and housing policy. A new plenary module on "Principles of Healthy HOllsing" 
will be incorporated into the Lead Poisoning Prevention Training Center (LPPTC) in the fall 
of 2007. Lead poisoning prevention training will be included in the Healthy Housing 
Training Center Network. LPPB will be responsible for managing both of these contracts. 
The next LPPTC session will be held on October 15-19, 2007. 
An article linking household mold to depression will be published in the October 2007 issue 
of the American Journal of Public Health. The eight-city study has been the lalrgest 
research project of its kind to date to demonstrate an association between mold and mood. 
The study also was the first investigation conducted outside of the United Kingdom. 
A Healthy Housing Expert Panel with ....35-40 scientists will be convened in December 2007 
with the following charge. State-of-the-art science on housing interventions that affec::t the 
health of residents will be identified and summarized. A consensus-based white papE!r will 
be developed that places interventions in one of three categories for action: (1) implement 
immediately, (2) conduct applied and evaluative research, or (3) conduct basic or formative 
research. A policy meeting is expected to be held within six months of the expert panel's 
publication to discuss and identify actual implementation strategies. 
CDC awarded LPPB discretionary funds of $167,000 to expand the Baltimore Lead 
Poisoning Prevention Program to include asthma, injuries, primarily burns, and deaths from 
house fires and carbon monoxide. Baltimore also will focus on sudden infant death 
syndrome, cabinet locks, safety gates, and the development of partnerships with non-·profit 
organizations. These activities will be conducted as part of Baltimore's existing assessment 
and intervention during home visits to children with EBLLs. 
Most of Baltimore's efforts will be designed to improve infrastructure. A database will be 
developed and training will be provided. A regulatory framework and curriculum will be 
created for sanitarians, code enforcement officials and other local officials. A "cookboc)k for 
transformation" will be developed and provided to LPPB with guidance for other lead 
programs that are considering a transition to healthy housing. 
ACCLPP Meeting Minutes Page 19 September 18-19, 2007 
Dr. Brown described LPPB's future activities to support its transition to a more holistic 
housing approach. For "budget-related" activities, LPPB made a request for report 
language in the 2008 budget to allow flexibility in using lead funds for healthy housing 
activities. LPPB hopes to increase the lead/healthy housing budget by $9.5 million in 2009 
to implement new strategies at state and local levels. LPPB also hopes to increase its 
personnel for the development of training curriculum and programs and more emphasis on 
healthy housing research projects. 
For "science-related" activities, an interagency Healthy Housing Surveillance Workgroup will 
be established with representation by CDC, the Agency for Toxic Substances and Disease 
Registry, EPA, HUD and the National Institutes of Health to identify data elements, 
determine existing data sources, and develop collaborative mechanisms. The work!~roup 
plans to hold its first meeting in October 2007. CDC is continuing the Green Buildings 
Study to determine levels of common allergens and environmental toxics in green built 
housing. CDC has conveyed its interest to HUD in evaluating health effects related to 
greening of tenant-based Section 8 properties. 
For "partnership-related" activities, the Tri-Agency Healthy Housing Conference will be~ held 
in October 2008 with CDC, EPA, HUD, and funded state and local programs. A meeting will 
be convened in the spring of 2008 with healthy homes grantees. Dr. Brown and CDC's 
Healthy Homes Goal Team Leader have been meeting with various groups to enlist new 
partners, including the Red Cross, Healthy Grandparents Programs and Meals on Wheels. 
Dr. Brown emphasized that the healthy homes activities will broaden and not replace 
LPPB's strong focus on the Healthy People 2010 goal for childhood lead poisoning. 
Dr. Warren Friedman, ACCLPP's ex-officio member for EPA, reported that HUD focus1es on 
a number of healthy homes issues, including lead poisoning, asthma and allergens, and 
indoor air quality. HUD takes a holistic and comprehensive approach to address multiple 
environmental health and safety hazards in housing. HUD designed this cost-eff.:!ctive 
approach to include preventive measures for reducing hazards, particularly in homes of low­
and very low-income families. 
HUD uses three mechanisms to implement its healthy homes activities. Under "grants and 
cooperative agreements," HUD has made 92 awards through FY'07 at a total of $72 million 
to its grantees throughout the country. HUD's grant programs include healthy homes 
demonstration projects for assessments, interventions, evaluation, and the development of 
assessment protocols and a weatherization assessment tool. 
Several healthy homes technical studies have been conducted under HUD's grants 
programs focusing on a characterization of housing stock; development of a methodol()gy to 
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detect and quantify mold spores; a cockroach cleaning protocol; and construction issues 
associated with Native American housing. 
Under "interagency agreements," HUD has produced a number of healthy homes 
documents, outreach materials and other products in partnership with CDC, the National 
Institute of Standards and Technology, and the U.S. Department of Agriculture. The Help 
Yourself to a Healthy Home booklet is one of HUD's most popular documents for 
consumers and can be downloaded in its entirety from the HUD web site. 
Under "contracts," HUD has contracted a variety of organizations to conduct hE~althy 
housing projects, such as research topic papers, technical documents, a listing of mold 
professionals, laboratory analysis of household dust allergen levels, and an evaluation of 
healthy housing initiatives. 
Dr. Friedman pointed out that HUD outreaches to communities in a number of its hE~althy 
homes activities to forge public-private, partnerships. For example, HUD provided technical 
assistance and developed best practice documents to help CLPPP staff and other state and 
local personnel in shifting from a sole focus on lead to a broader healthy homes approach. 
HUD provided integrated pest management training to public health authorities and 
environmental safety training to contractors following Hurricane Katrina. 
Dr. Friedman summarized a number of HUD's healthy homes initiatives. HUD will continue 
to support the Surgeon General's Call to Action for Healthy Housing. HUD will continue to 
participate in healthy homes conferences and also will increase regional and local 
collaborations. The HUD Office of Affordable Housing Program has a green initiative that is 
being piloted in Lawton, Oklahoma. The project is designed to incorporate green principles 
into housing construction and assess practices in the home after green construction. 
HUD launched a campaign in April 2006 to outreach to 30 cities throughout the country over 
a three-year period. In this campaign, HUD collaborates with local groups to display its 
"Healthy Homes Pavilion" at local events. The interior of the pavilion contains sign:; that 
identify potential housing conditions, such as moisture problems from freestanding water 
and lead hazards from deteriorated paint. 
Dr. Friedman outlined HUD's future strategies to enhance its healthy housing initiatives. 
Programs will be expanded to increase the focus on healthy, energy efficient and affordable 
housing. Demonstration projects and other healthy housing activities will continue to be 
research-based with more formal analyses and assessments to ensure the application of 
these projects in the future. Interagency collaboration will be expanded as well. 
Dr. Friedman pOinted out that HUD issued a press release on September 13, 2007 
announcing its allocation of $143 million in grants to protect children from dangerou~; lead 
and other health and safety hazards in the home. The press release was distributed to 
ACCLPP for review. 
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ACCLPP commended CDC on expanding LPPB's focus from childhood lead poisoning 
prevention to include a broader healthy housing approach. ACCLPP also was pleased that 
CDC, HUD and other federal agencies have established a true partnership in this effort. 
Several ACCLPP members made suggestions for the federal agencies to consider in 
ongoing efforts to strengthen and expand healthy housing initiatives. 
• 	 The federal agencies should make better use of local data in the hE~althy 
housing initiatives because some of this information is not available at the 
federal level. For example, local data can include information on rodents, 
mold and pesticide use in small geographic areas of certain jurisdictions. 
• 	 The federal agencies should assist local jurisdictions in developing model 
legislation on healthy housing. 
• 	 The federal agencies should attempt to develop and reach consensus on one 
definition of "green" during the ongoing healthy housing collaborative efforts. 
• 	 The federal agencies should engage non-traditional partners in the healthy 
housing initiatives, such as MRP and large insurance companies that can 
play an important role in prevention, advocacy and policy development. 
• 	 The federal agencies should use valuable environmental data that will be 
generated from the National Children's Study to inform the healthy homes 
initiatives. 
• 	 CDC should conduct formal clinical trials in addition to observational research 
as progress is made on the healthy homes initiative. For example, a study 
could be performed on the remediation of mold with no other improvements 
made in the home. These findings could be used to determine whethl~r the 
sole remediation of mold in the home made an impact on depression. 
Dr. Brown made several remarks in response to specific questions posed by the ACGLPP 
members. First, the new interagency Healthy Housing Surveillance Workgroup will begin to 
identify existing data sets during its first meeting in October 2007. This effort will allow the 
workgroup to propose healthy homes benchmarks in the future. 
Second, Dr. Brown provided guidance to states with an interest in incorporating the five 
guiding principles of the healthy housing framework for action into existing programs. 
Training should be provided to staff in local and state lead programs and other age!ncies 
beyond local and state health department personnel. To facilitate this effort, the Healthy 
Housing Training Center Network offers a 2.5-day training session in nine academic 
settings across the country. 
Dr. Brown also pointed out that states and local jurisdictions must seriously consider the 
regulatory framework, costs and other important issues associated with incorporating a 
healthy housing framework into existing programs. 
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Third, Dr. Brown confirmed that she would give some thought to potential strategies for 
CDC to obtain external advice on the healthy homes initiative. However, she emphasized 
that several important issues would need to be considered. On the one hand, ACCLPP is 
federally chartered to provide guidance and recommendations to the HHS Secretary and 
CDC Director on childhood lead poisoning prevention. An expansion of ACCLPP's focus to 
include healthy homes issues would require a new charter. 
On the other hand, an entirely new healthy homes advisory committee could be established 
in addition to ACCLPP. However, CDC is more interested in convening expert panels to 
provide advice on specific issues rather than forming new federal advisory committees. 
Overall, Dr. Brown clarified that decisions on this issue would be premature at this point 
because the healthy homes initiative is in its infancy. However, she thanked ACCLPP for 
raising this important issue at this time because the terms of several members would e,xpire 
in 2008. The healthy homes initiative would provide ACCLPP with an opportun ity to 
determine whether potential candidates in 2008 should be recruited based on their 
expertise in lead, healthy homes, or a combination of both disciplines. 
Dr. David Jacobs, of NCHH, explained that the LlHTC program is operated by the 
Department of Treasury and is the federal government's largest program for new housing 
construction and rehabilitation of low-income properties. In 2007, each state received $1.95 
per person under the LlHTC program or a total of $500 million. Private investors, 
syndicators and developers contributed additional leveraged funds on the order of hundreds 
of millions of dollars. 
The LlHTC program requires units to have a "low-income" status for 15-30 years. Since 
1986 when the program was established, 1.9 million units have been rehabilitatE!d or 
constructed. Slightly less than 500,000 units were built before 1978 and are likely to have 
lead paint. 
Dr. Jacobs summarized an evaluation of the LlHTC program. Processes widely vary for 
states to administer the LlHTC and address lead paint issues. Each state and some large 
cities develop qualified allocation plans (QAPs) to determine strategies to award credits. Of 
52 QAPs, only 15 explicitly address lead-based paint (LBP). Of these 15 QAPs, only four 
specifically state that LBP hazards are required to be eliminated or controlled during 
rehabilitation of older housing units. These findings indicate that 74% of rehabilitated 
housing units under the LlHTC program do not have LBP requirements. 
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States have the option of administering the LlHTC program through state housing codes or 
HUD Uniform Physical Condition Standards (UPCS). Private underwriting standards do not 
provide specific LBP requirements. Federal Housing Authority regulations cover LBP, but 
are limited to multi-family mortgage insurance and HUD-owned single-family dwellings sold 
with a HUD-insured mortgage. Single-family mortgage insurance regulations covering 
single-family units not being sold were not updated in HUD's most recent LBP regulations in 
2000. 
The Internal Revenue Service (IRS) recently issued guidance materials noting that HUD's 
lead-safe housing rule applied to each state that used UPCS as its inspection standard. 
However, no specific details were provided on applicable parts of the regulation, such as 
rehabilitation. States that do not select UPCS are not under an affirmative responsibility to 
follow any lead-safe procedures unless another federal or state local authority requires 
compliance. The IRS has not issued any training materials on lead-safe practices. 
In 2003, the IRS failed to execute a proposed memorandum of understanding (MOU) with 
HUD and the Department of Agriculture to clarify LBP issues in the low-income housing tax 
credit program. However, HUD and the Department of Treasury had previously executed 
an MOU regarding fair housing requirements. As a result, fair housing is now addres~;ed in 
all QAPs. The IRS provides written instructions for persons to complete and submit Form 
8823, "Low-Income Housing Credit Agencies Report of Noncompliance or Building 
Disposition," with their tax returns. 
A formula was developed to estimate the number of housing units in the LlHTC program 
that would have been at risk for LBP hazards from 1986-2006. The formula projected that 
193,000 housing units might have been rehabilitated with no lead requirements ov€!r this 
six-year period of time and that 14,200 housing units would have been at risk annually for 
each of the six years. 
Dr. Jacobs informed ACCLPP that CDC administered a survey to CLPPP grantees with the 
following questions: (1) What is the number of programs that are aware of the LlHTC? (2) 
Are programs aware of QAPs? (3) Do these QAPs address lead? (4) What is the 
program's relationship with HUD and local housing agencies in administering the LlHTC? 
(5) What are the next steps regarding the inclusion of lead elements in QAPs in your 
project? (6) When will the QAP be drafted and finalized for the upcoming final project year? 
The survey to CLPPPs showed the following results. Of 42 respondents, only 23 pro~lrams 
were aware of the LlHTC; 13 programs that were not aware of the LlHTC performed 
research to investigate this issue; six programs had no knowledge of the LlHTC; and nine 
programs had knowledge of QAP strategies to specifically address lead. The survey also 
showed that several states had limited relationships with HUD and state housing agem:ies. 
CLPPPs should be educated on the possible use of the LlHTC for lead poisoning 
prevention. Property owners, developers, investigators, syndicators and local housing 
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agencies should incorporate specific lead requirements in QAPs and award additional 
points for lead hazard control, particularly for low-income eligible populations. 
Communications should be improved with state and local housing agencies and between 
ClPPPs and HUD. 
A template should be developed to incorporate lead poisoning prevention language into all 
QAPs. The model for Fair Housing requirements should be reviewed in this effort. Federal 
rules should be clarified to include lead as a requirement in QAPs. States should closely 
partner with state housing agencies to draft, establish and document lead paint 
requirements into appropriate QAPs. ClPPPs and state and local housing agencies should 
collaborate to review and modify QAPs on an annual basis. 
EPA, HUD, and state and local housing agencies should be included in existing or 
upcoming coalitions, partnerships, and strategic adviSOry committees. QAPs should 
consider dust, soil, ventilation, moisture and other non-paint issues due to the transition 
toward healthy homes. A listing of state and city QAPs that award points for green 
rehabilitation and construction should be developed and widely distributed. 
Dr. Jacobs asked ACClPP to consider several key questions during its ongoing discussions 
on healthy housing: (1) What strategies should be implemented to address non-paint 
issues? (2) Should non-paint issues be included in QAPs? (3) Who has responsibility of 
non-paint issues? (4) Who is responsible for assuring that lSWPs are used in LlHTC 
rehabilitation? (5) Should contractors be required to show proof of lSWP training? Dr. 
Jacobs informed ACClPP that the entire LlHTC report is available to the public on the 
Alliance for Healthy Homes web site at: 
Dr. Rhoads explained that he structured his presentation with three major objectives. First, 
recent results concerning the effects of low-level lead exposures would be reviewed in the 
context of changes in Blls in U.S. children over the past few decades. Second. study 
design issues would be reviewed to identify sources of possible bias. Third, strategies 
would be proposed for studies that might resolve some of the ambiguities in what is ~;nown 
about the effects of Blls <10 1J9/dL. 
Several studies have been conducted that relate childhood blood lead at levels < 10 1J9/dl 
to developmental outcomes. A prominent finding has been that the relationship between 
blood lead at these low levels is more strongly related to outcomes, such as IQ and reading 
scores, than was reported from older studies conducted when children had higher Blls. 
Thus, according to these findings, a change in blood lead from 10 1J9/dl to 5 1J9/dl would 
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make more difference to developmental outcomes than would a change from 15 1J9/dl to 10 
IJg/dL. 
This somewhat unexpected result may not be fully consistent with the U.S. national 
experience. NHANES data showed a dramatic decrease in Blls among U.S. children 1-5 
years of age from 15 1J9/dl in 1976-1980, to 3.6 IJg/dl in the early 1990s, and to 1.9 1J9/dl 
in 1999-2002. Based on coefficients reported by Canfield et al., 10 was predicted to 
improve in children three years of age by 1.5 points with a decrease from 15 to 1 0 ~g/dl 
Bll and by a striking 8.7 10 points with a decrease from 10 to 3.6 IJg/dl BlL. 
On a population basis in the United States, coefficients from this study would predict a 
nationwide improvement of 10.2 10 points by the early 1990s with further improvE!ment 
since that time. This is a very large predicted improvement, but no consensus has been 
reached among psychologists and educators that such a remarkable change occurred. 
A cross-sectional analysis was performed in 2000 with NHANES III data. This national 
sample included 4,816 children 6-16 years of age. Venous blood lead was collected and 
the children completed several measures of psychological function and school 
achievement. The analysis showed that the coefficient relating reading scores on the Wide 
Range Achievement Test-Revised (WRAT-R) to Bll were 0.99 for all children and 1.!53 for 
those who had never had a Bll >7.5 1J9/dL. 
The arithmetic subtest coefficient was 0.70 in all children and 1.06 in children with peak 
Blls <7.5 1J9/dL. When these coefficients were applied to the change in Bll that was 
actually documented for the United States between 1976-1980 and the early 1990s, they 
implied an improvement of 13.4 points on the WRAT-R reading score. However, actual 
tracking of reading scores in children nine years of age by the National Educational 
Assessment Survey revealed no sign of such a change. 
Dr. Rhoads described sources of possible bias in the studies. All studies relating blood lead 
to neurodevelopment of children were observational and could be biased by diffen:mces 
between highly exposed and less exposed children. Although many such factors were 
taken into account, elimination of all of the important differences cannot be assured in 
observational studies. 
Points of particular concern are whether children with less intellectual and academic 
potential might, on average, have more hand-to-mouth activity as toddlers or whether 
parents who organize their homes and childrearing practices in ways that minimiZE! lead 
exposure might also provide more developmental stimulation for their children. These types 
of confounding could account for the steeper Bll-IO curves that have been recently 
reported as was noted in the 2005 CDC document on this topic. 
The finding of reverse causality based on an 10 relationship at 10 1J9/dl was not widely 
predicted when the level of concern was established at 10 IJg/dL. Exact predictions could 
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not be made with scenarios where children with less IQ potential had more hand-to-mouth 
activity or more opportunity to ingest non-foods. 
Dr. Rhoads then outlined some possible future directions regarding this issue. Despite the 
caveats outlined above, recent studies are worrisome. Better research is needed to 
address existing uncertainty and determine whether the relationship between IQ and low 
BLls is real and is of substantial magnitude. IQ-blood lead slopes reported in recent low­
level studies appear to be too steep to be entirely credible. Steeper blood lead or .an IQ 
curve at low Blls suggests possible reverse causality. However, these considerations 
should not rule out an important 10 effect at low BLLs. 
More observational studies adhering to the same basic designs that have been previously 
used are likely to be subject to the same biases as those recently reported and might never 
provide a basis for deciding when Blls are low enough. A randomized primary prevEmtion 
trial would be the best strategy to clarify these issues, but might be difficult to implement. 
Observational studies with different designs might be helpful. 
New observational studies should be designed with a measure of exposure that is 
independent of ingestion, such as a study on the IQs of siblings raised in different housing 
with different levels of lead exposure. Non-lead markers should be identified to assess non­
food ingestion and control for the association between blood lead and IQ. Genomic 
approaches should be used to identify single nucleotide polymorph isms or haplotypes that 
place children at risk. 
To conduct a randomized prevention trial, a situation where phased housing intervention is 
being implemented to reduce lead exposure should be located. Families should be 
assigned to the improved housing in a fair and random manner. Differences in blood lead 
should be measured between the two groups. Developmental measures in children raised 
in new housing with low lead levels should be compared to children raised in old housing. 
ACClPP extensively discussed the advantages and disadvantages of lowering the Bll of 
concern. Most members agreed with Dr. Rhoads' proposal to conduct a randomized 
prevention trial. The members made two key suggestions that should be consider,ed as 
ACCLPP continues this discussion in the future. 
First, CDC should maintain, clarify and strengthen its focus and investments on primary 
prevention and healthy housing for community interventions to be implemented at BlLs <10 
j.lg/dL. No interventions are available at this time to support public interest in lowering the 
Bll of concern to <10 j.lg/dL. Second, CDC should eliminate its language of a "Bll of 
concern" because the agency has no regulatory authority to mandate a threshold for le·ad. 
In its future discussion on this issue, Dr. Brown encouraged ACClPP to consider lowering 
the Bll of concern to <10 j.lg/dl from both public health and pragmatic perspectives. 
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Dr. Jacobs advised CDC to define Blls 1-10 jJg/dl as "above average." This approach 
would eliminate public confusion about "levels of concern" or specific interventions to 
implement. 
Mr. Jack Bradham, of the Hennepin County Health Department, announced that Hennepin 
County would meet the Healthy People 2010 objective of "0 EBlls" if current trends in Blls 
continued and the Bll threshold continued to be defined at 10 jJg/dL. Due to the difficulty 
in defining "0 EBlls," Mr. Bradham asked ACClPP to provide guidance on a pragmatic 
definition, particularly in light of newly arrived immigrant children and rare fatal lead cases. 
Dr. Brown explained that CDC has proposed the following definition of achievin!~ the 
Healthy People 2010 goal for childhood lead as a public health problem based on NHANES. 
NHANES would be administered as currently constructed. If the prevalence of Blls >10 
jJg/dl was low enough so that no child would be identified with a Bll ~10 jJg/dl in 95 out of 
100 trials, this result would be consistent with achieving the Healthy People 2010 goal for 
childhood lead as a public health problem. 
With no further discussion or business brought before ACClPP, Dr. Rhoads recessed the 
meeting at 5:35 p.m. on September 18, 2007. 
Dr. Rhoads reconvened the ACClPP meeting at 8:33 a.m. on September 19, 200i' and 
yielded the floor to the first presenter. 
Dr. Jessica leighton, an ACClPP member and chair of lPWG, provided a status rep()rt on 
lPWG's activities following the March 2007 meeting. Because lPWG located only a 
minimal amount of data to support some of the recommendations, she asked ACClPP to 
extensively critique the recommendations for each chapter of the lead and pregnancy 
report. She confirmed that the lack of data would be highlighted as a caveat in the report. 
Dr. leighton pointed out that since lPWG's update to ACClPP in March 2007, the chapters 
of the lead and pregnancy report were revised as follows: 
• Chapter 1: Introduction 
• Chapter 2: Adverse health effects of exposure to lead 
• Chapter 3: Biokinetics and biomarkers of lead in pregnancy and lactation 
• Chapter 4: Sources and pathways of lead exposure in pregnant women 
• Chapter 5: Identification and follow-up of EBlls in pregnancy and infam:y 
• Chapter 6: Environmental, behavioral, nutritional and medical management 
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• 	 Chapter 7: Indications, contraindications and adverse effects of chelation in 
the pregnant woman, fetus and newborn infant 
• 	 Chapter 8: Breastfeeding 
• 	 Chapter 9: Research, policy and health education needs 
Dr. Leighton summarized key points and recommendations in the chapters of the lead and 
pregnancy report. The following points are emphasized in Chapter 1: "Introduction." Lead 
exposure remains a public health problem for women of childbearing age, the developing 
fetus and nursing infant. Evidence has been produced on the effects of lead on maternal 
and infant birth and neurodevelopment outcomes. 
Bone lead stores were previously considered to be inert, but are mobilized in pregnancy 
and lactation. Certain population subgroups are at high risk for exposure, including workers 
in high-risk occupations, foreign-born recent immigrants, and persons practicing pice:' and 
other high-risk behaviors. Medical and public health providers have sought guidance fm the 
identification, treatment and follow-up of lead-exposed pregnant and lactating women and 
prenatally exposed infants. 
The following points are emphasized in Chapter 2: "Adverse health effects of exposure to 
lead." Lead exposure is associated with increased risk of hypertension. However, a 
magnitude of effect, exposure level at which risk increases, and association between risk 
and acute or cumulative exposure have not been established to date. Some evidence has 
been produced to support an association between moderate levels of maternal lead 
exposure and spontaneous abortion. 
Inconsistent associations have been seen between maternal lead exposure and risk of 
preterm delivery. Data are inadequate to establish the presence or absence of an 
association between maternal lead exposure and major congenital anomalies in the fetus. 
Epidemiologic cohort studies suggest that even with maternal BLLs <10 1J9/dL, prE~natal 
exposure to lead is inversely related to fetal growth and neurobehavioral development 
independent of effects of postnatal exposure. 
The following points are emphasized in Chapter 3: "Biokinetics and biomarkers of IE!ad in 
pregnancy and lactation." No accurate measure of total body lead been established to 
date. Biological markers are used to estimate lead body burden and assess lead d()se to 
the fetus during pregnancy and to the infant during lactation. BLLs are the most well 
validated and widely available measure of lead exposure. However, a single blood lead 
measure at a given point in time will not provide an accurate indication of cumulative 
exposure or risk to the fetus or infant. Repeat testing might be necessary. 
Bone is a potential source of endogenous lead exposure. Cumulative maternal bOnE! lead 
stores are mobilized during pregnancy and lactation. However, bone lead measurement is 
a research tool that is not available for routine clinical application. Lead readily crosses the 
placenta by passive diffusion and has been measured in the fetal brain as early as the end 
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of the first trimester. As a result, primary prevention of exposure is particularly important to 
reduce risk. Given the difficulty of accurately and precisely measuring trace amounts of 
lead in human breast milk, routine measures of breast milk lead should not be used for 
routine clinical application. 
The following recommendations are highlighted to prevent or reduce lead exposure in 
pregnant women in Chapter 4: "Sources and pathways of lead exposure in pregnant 
women." Clay, soil, pottery, paint chips and other non-food items should never be eaten. 
Jobs or hobbies that might involve contact with lead should be avoided, such as 
construction work, home renovation or repair, furniture refinishing, and work inv()lving 
firearms, arts and crafts, ceramics, stained glass, metals or color pigments. 
Imported clay pots and dishes should not be used to cook, serve or store food. Chipped or 
cracked pottery should not be used. Repair work and remodeling on homes built before 
1978 should be avoided. Health remedies and kohl, kajal, surma and other eye cosmetics 
from other countries should be avoided. Caution should be taken when consuming candies, 
spices and snack foods made in other countries. A balanced diet should be eaten with 
adequate intakes of iron and calcium. Table 4-1 contains an extensive list of risk factors for 
EBLLs in pregnant women. 
The following recommendations are highlighted for blood lead screening in Chapter 5: 
"Identification and follow-up of EBLLs in pregnancy and infancy." Universal blood lead 
testing of all pregnant women in the United States is not recommended. Routine bloocllead 
testing of pregnant women is recommended in clinical settings serving populations at high­
risk for lead exposure. In clinical settings where routine blood lead testing of pregnant 
women is not indicated, healthcare providers should consider the possibility of lead 
exposure in all pregnant women by evaluating risk factors for exposure. 
The presence of specific risk factors indicates the need for blood lead testing. 'Nhen 
indicated, blood lead testing should take place at the earliest contact with the pregnant 
patient and also should be performed using venous blood lead tests. State or local public 
health departments should identify high-risk populations of pregnant women to guide 
clinicians in determining the need for blood lead testing. Follow-up blood lead testing is 
indicated for pregnant women with BLLs IJg/dL and their infants. 
Pregnant women with confirmed BLLs ~45 1J9/dL should be considered as high-risk 
pregnancies and managed in consultation with an expert in lead poisoning and high-risk 
pregnancies. Tables 5-1 through 5-4 contain the following information: (1) recommended 
actions by BLL in pregnancy; (2) frequency of maternal blood lead follow-up testing during 
pregnancy; (3) follow-up of initial blood lead testing of the neonate <1 month of age; and (4) 
schedules for subsequent follow-up blood lead testing in infants <6 months of age. 
The following recommendations are highlighted for avoidance of lead exposure in Chapter 
§: "Environmental, behavioral, nutritional and medical management." Point sources of 
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exposure should be identified and eliminated or controlled. Occupational exposures should 
be avoided. Personal protective equipment should be used. 
Recreational activities that might involve lead exposure should be avoided. Drinking of 
lead-contaminated tap water should be avoided either by using bottled or filtered water or 
flushing the tap. Pica behavior is common among women identified with high Blls in 
pregnancy and should be assessed and discouraged. 
If renovation, remodeling or repairs are undertaken in homes built before 1978 with lead 
paint or paint with unknown lead content, pregnant and lactating women should be 
protected from lead exposure by adhering to EPA's lSWPs, including isolation from the 
work area. Products that might contain lead should be avoided, including culturally-specific 
products produced outside of the United States and ceramics, herbal medicines, cosmetics, 
foods, spices and candies. 
The following nutritional recommendations are highlighted in Chapter 6. All pregnant and 
lactating women should be evaluated for the adequacy of their diets and should be provided 
with appropriate nutritional advice and prenatal vitamins. Adequate nutrition should be 
maintained throughout pregnancy and lactation. 
The following actions should be taken for pregnant and lactating women with EBlls, or a 
history of EBlls. A dietary calcium intake of 2,000 mg daily should be maintained either 
through diet or supplementation or a combination of both. Iron status should be evaluated 
and supplementation should be provided to correct any iron deficiency. 
The following medical management recommendations are highlighted in Chapter 6. 
Pregnant women with confirmed Blls ~45 1J9/dl should be considered as "high-risk" and 
managed in consultation with lead poisoning and high-risk pregnancy experts. Pre!~nant 
women with confirmed Blls <45 1J9/dl should be retested according to the schedu'es in 
Chapter 5 and Chapter 8 if breastfeeding. Table 6-1 contains a list of suggested factms to 
assess and characterize pica behavior. 
The following recommendations are highlighted for chelation therapy in Chapter 7: 
"Indications, contraindications and adverse effects of chelation in the pregnant weIman, 
fetus and newborn infant." Chelation treatment should be considered for pregnant women 
with Blls >45 1J9/dl and if organogenesis is complete (i.e., after the first trimester). The 
decision to chelate should be performed in consultation with an expert. 
Pregnant women with life-threatening lead encephalopathy should be chelated regardless 
of trimester. Before considering chelation therapy in the pregnant woman or infant, Blls 
should be repeated and confirmed using an additional venous blood lead sample collected 
within 24 hours. Chelation treatment must occur in a lead-free environment. As a result, 
the patient should be removed from further lead exposure prior to initiating chelation 
therapy. 
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Pregnant women with confirmed BLLs ~45 IJg/dL should be considered as "high-risk" and 
managed in consultation with lead poisoning and high-risk pregnancy experts. Infants 0-6 
months of age with confirmed BLLs ~45 IJg/dL should be considered as candidates for 
chelation in consultation with a pediatric expert in lead chelation therapy. Tables 7-1 and 7­
2 contain the following information: (1) chelating agents used to treat lead poisoning and 
(2) published experience with chelating agents during pregnancy in humans. 
The following recommendations are highlighted for breastfeeding in Chapter 8. Due to the 
possibility of an increase in BLLs during lactation, a woman with BLLs ~20 1J9/dL identified 
during pregnancy should have BLLs monitored during lactation. Women with confirmed 
BLLs ~40 1J9/dL should not breastfeed unless the mother and baby are closely monitored. 
At maternal BLLs between 20-40 1J9/dL, data do not exist to accurately weigh the risks of 
lead exposure from breast milk against the benefits of breastfeeding. At these levels, the 
woman may continue to breastfeed if sequential BLLs of the mother and infant are 
performed to monitor trends in BLLs. If these sequential BLLs do not decline as expected, 
extra attention should be paid to identifying ongoing sources of lead in the mother-infant 
pair. Specifically, a thorough investigation of the child's environment should be performed 
to evaluate the possibility of additional lead sources. 
Tables 8-1 through 8-4 contain the following information: (1) frequency of maternal blood 
lead follow-up testing during lactation to assess risk of infant lead exposure from maternal 
breast milk; (2) recommended values estimated for breast milk intake by age in months; (3) 
estimated daily intake of lead from breast milk at different maternal blood lead 
concentrations; and (4) estimated infant blood lead concentration associated with different 
maternal blood lead concentrations. 
LPWG will develop key recommendations for research, policy and health education needs 
for Chapter 9 during its next meeting. 
ACCLPP commended Dr. Leighton and the other LPWG members for developing a 
document on an extremely complex issue. ACCLPP acknowledged that LPWG has been 
challenged in creating the lead and pregnancy report due to the lack of data to support 
certain recommendations. 
Several ACCLPP members made suggestions for LPWG to consider in its ongoing efforts to 
revise the report. 
• Chapter 1: New language should be added to the introduction to outline the 
anticipated impact of screening pregnant women on clinical practice. 
• Chapter 2: "Moderate" should be characterized with a specific range because 
laboratories do not define BLLs as elevated until 25 1J9/dL. 
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• 	 Chapter 3: Language should be added to clarify that x-ray and breast milk 
are not practical at this point in time because both of these factors could 
change in the future. 
• 	 Chapter 4: More emphasis should be placed on hand-to-mouth activities 
related to pica in addition to actual consumption of non-food items. 
• 	 Chapter 4: A recent paper that quantifies tobacco use as a source of lead in 
pregnant women should be referenced. Dr. Binns will provide LPWG with the 
citation of the paper. 
• 	 Chapter 4: Language should be added to explicitly identify a "child" as 
another individual with an EBLL who lives with a pregnant woman. 
• 	 Chapter 5: A general statement should be added to advise pre-conceptual 
care providers to consider risk factors. 
• 	 Chapter 5: Language should be added to clarify that if the provider uses a 
questionnaire, the questions should be modified to be relevant and specific to 
local needs. 
• 	 Chapter 5: Language should be added for states to develop strategies to 
identify and track patients through blood lead reporting systems. 
• 	 Chapter 5: Papers in the literature that recommend medical removal of 
pregnant women from occupational lead exposure should be cited, sUl::h as 
the article on Recommendations for Medical Management of Adult Lead 
Exposure that was published in March 2007. Although the OSHA threshold 
for medical removal is 50 IJg/dL, a proviso in the OSHA regulations authorizes 
physicians to recommend medical removal at any BLL if a woman has a 
health condition that places her at increased risk of lead exposure. Dr. 
Kosnett will provide LPWG with language to address this issue. 
• 	 Chapter 5: LPWG should discuss and reconsider the threshold of 5 1J9/dL for 
screening of pregnant women. Laboratory capacity is not sufficient to 
quantify lead at BLLs <10 IJg/dL in pediatric screening and a considerable 
amount of uncertainty exists with BLLs <10 IJg/dL. This outcome would be 
the same for screening pregnant women. Dr. Parsons will provide LPWG 
with language to address this issue. 
• 	 Chapter 5: The first BLL columns in Tables 5-1 through 5-4 should all bo "<5" 
for consistency. 
Chapter 5: The "~4" column in Table 5-1 should be revised as fo.l!ows; 
"Healthcare providers should routinely give anticipatory guidance to all 
pregnant women who work in industries where they could be exposed to lead 
and whose BLLs are low or unknown." 
• 	 Chapter 5: "Source reduction" should be moved from the "15-44" column in 
Table 5-1 and placed in the "5-9" column to clarify "identification of lead 
sources and reduction." 
• 	 Chapter 5: Language in the "15-24" column of Table 5-2 should be changed 
as follows. "At the next visit or in one month, a blood lead test between 15-14 
should be repeated." 
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• Chapter 5: The title of Table 5-4 should be clarified to ensure that the 
guidance is not interpreted to mean blood lead testing in infants <6 months of 
age should be performed. 
• Chapter 5: The guidance should be changed in Table 5-4 to advise referral to 
a specialist earlier than BLLs ~45 ~g/dL. 
• Chapter 6: Language should be added to the nutritional recommendations to 
emphasize that adequate vitamin 0 is necessary for calcium absorption. 
• Chapter 6: LPWG should engage obstetricians in a dialogue regarding 
potential changes to the two medical management recommendations. For 
example, the first recommendation should clearly define the BLL that should 
be considered as a high-risk pregnancy. "High-risk pregnancy" shou ld be 
clearly defined to mean a physician-lo-physician consultation rather than a 
referral of the patient to a high-risk obstetrician. Language in the sE!cond 
recommendation should be changed to "retested and advised." 
• Chapter 6: The medical management section should advise pregnant w()men 
to seek additional advice by consulting with lead poisoning experts. The 
types of providers that can provide expertise in lead poisoning shou ld be 
described. 
• Chapter 6: A new column should be added to Table 6-1 to specify whether 
actions should be taken based on outcomes in assessing and characterizing 
pica behavior. 
• Chapter 6: Headers should be added to Table 6-1 to clarify and distinguish 
among "personal pica," "substances consumed," and "community context " 
• Chapter 7: The term should be changed to "lead-safe environment" in the 
chelation therapy recommendations. 
• Chapter 7: Language should be added to the chelation therapy section to 
clarify that sufficient data are not available to make a recommendation on 
chelating infants 0-6 months of age at BLLs <45 ~g/dL. The provider should 
be advised to consult with a medical toxicologist. 
• Chapter 7: The second and third breastfeeding recommendations should be 
switched to discuss BLLs 20-40 ~g/dL first, followed by BLLs ~40 ~g/dL. 
• LPWG should add a new appendix with three sections on "understanding 
BLLs in pregnancy." One, expected BLL patterns in pregnancy should be 
clearly described. Two, language on interpreting laboratory uncertainties 
should be extracted from ACCLPP's <10 clinical paper. Three, the false­
negative/false-positive table at a threshold of <5 ~g/dL that Ms. Blumenthal 
presented during the meeting should be replicated. Dr. Parsons will assist 
LPWG in developing the new appendix. 
Dr. Leighton thanked ACCLPP for providing LPWG with valuable feedback. She ask·ed the 
members to submit additional comments in writing by November 1, 2007 in preparation of 
LPWG's next meeting on November 8, 2007. An electronic version of the report and 
references would be circulated to ACCLPP to facilitate the submission of comments. Dr. 
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Leighton planned to present the full lead and pregnancy report during the March 2008 
ACCLPP meeting. 
Dr. Brown described CDC's next steps in the lead and pregnancy report. CDC would draft 
policy and research recommendations for Chapter 9. As a scientifically influential document 
from a federal agency, the report would be required to undergo separate clearance 
processes at CDC, HHS and the Office of Management and Budget. The cleared document 
would then need to be peer reviewed by three outside experts with no conflicts of interest in 
the subject matter. 
Dr. Brown estimated that after ACCLPP formally approved the final draft, the report would 
not be published for two years due to the clearance, peer review and final editing 
processes. However, the two-year lag would provide an opportunity for CDC and the 
authors of the report to incorporate new data produced during this time. CDC also would 
coordinate efforts with OSHA and the National Institute for Occupational Safety and Health 
to ensure that the lead and pregnancy report was consistent with guidance documents 
produced by these agencies. Alternatively, CDC would need to provide a strong rationale 
for any inconsistencies between the documents. 
At a future meeting, Dr. Brown planned to engage ACCLPP in a discussion bout 
publication options. For example, the lead and pregnancy report could be published as a 
standalone document, in the MMWR, or in an obstetric or pediatric journal. She confirmed 
that CDC has informed state health departments about the timeline for the upc()ming 
publication of the document. 
Ms. Jane Malone, chair of MCWG and the ACCLPP liaison to the Alliance for Healthy 
Homes (AFHH), provided a status report on MCWG's activities following the March 2007 
meeting. MCWG discussed and reviewed proposals to submit to the International Code 
Council (ICC) on international property maintenance codes (IPMCs). MCWG distributed 
and received comments from ACCLPP on its draft position statement to improve IPMCs to 
prevent exposure to LBP hazards. 
ICC adopted several proposals in its 2006-2007 code change cycle that ended in May 2007, 
but none of MCWG's proposals were accepted. MCWG's proposals focused on expanding 
language in the IPMCs from "ensuring no peeling paint" to include "appropriately addressing 
deteriorated LBP." MCWG's proposals also explicitly defined LSWPs and added a 
clearance requirement. 
Ms. Malone announced that ICC initiated its new code change cycle with the first hearings 
to be held in March 2008. ICC will consider changes to the IPMCs that AFHH and NCHH 
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jointly submitted in August 2007 during the first hearing in March 2008. The AFHH/NCHH 
changes focus on painted surfaces in interior properties and clearly define practices that are 
prohibited in repairing deteriorated LBP. The AFHH/NCHH changes were distributed to 
ACCLPP for review. 
Dr. Brown reminded the members that at a previous meeting, ACCLPP unanimously 
approved sending a letter to ICC. The draft letter highlights ACCLPP's recommendations 
for the IPMCs to explicitly and effectively prohibit the creation of LBP hazards and also to 
enforce LSWPs. The letter references AFHH's web site for readers to obtain more 
information on specific standards. 
Dr. Brown informed ACCLPP that the draft letter was submitted to the CDC clearance 
process and is expected to be approved over the next 30 days. The CDC-cleared letter will 
then be forwarded to the HHS Secretary for informational purposes only. After the 3D-day 
period expires, Drs. Brown and Rhoads will sign and send the letter to ICC. The draft letter 
was distributed to ACCLPP for review. 
In response to specific questions posed by ACCLPP members, Dr. Brown confirmed that 
the letter could be circulated to trade association publications in addition to ICC. She 
clarified that after CDC's formal approval and clearance, the letter would be in the public 
domain and could be reprinted in any venue. The letter also would be posted on ACCLPP's 
web page on the CDC web site. 
~ -. , .-.-, T -:J::i 
~ 
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Dr. Rhoads opened the floor for the members to revisit outstanding items or prOpOSE! new 
topics that need action by ACCLPP. 
Dr. Kosnett asked ACCLPP to consider developing language on the interpretation of clinical 
laboratory report forms for blood lead testing. He pointed out that ACCLPP's guidance 
could assist in minimizing variability and enhancing consistency among clinical laboratory 
forms in interpreting lead concentrations, 
Dr. Kosnett proposed that the laboratory workgroup's charge could be expanded to address 
these issues. However, the workgroup's membership would need to be broadened to 
include persons with experience and expertise in interpretation issues. Alternatively. an 
entirely new "Interpretation Workgroup" could be established. 
Dr. Brown asked ACCLPP to delay taking action on Dr. Kosnett's proposal until Dr. Parsons 
submits clinical laboratory language to LPWG. ACCLPP could make a decision at that time 
on whether a new "Interpretation Workgroup" would be needed or if the voting members 
would simply need to vet Dr. Parsons' language. Overall, Dr. Brown reminded ACCLPP of 
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its federal charter to provide advice on lead poisoning prevention of children and not adults. 
She also emphasized the resource constraints in forming a new ACCLPP workgroup. 
ACCLPP extensively discussed Dr. Kosnett's proposal to address the interpretation of 
clinical laboratory report forms for blood lead testing. Although ACCLPP agreed with Dr. 
Kosnett on the importance of addressing this issue, the majority of voting members were 
unable to reach consensus due to the caveats and limitations outlined by Dr. Brown in 
undertaking this effort. 
Dr. Brown proposed the following process to resolve ACCLPP's dilemma. She would 
consult with CDC's laboratory staff to identify contacts in commercial laboratories, and 
determine whether an easy mechanism could be implemented to address the interpretation 
of clinical laboratory report forms for blood lead testing. After Dr. Brown reported her 
findings to ACCLPP during the March 2008 meeting, the voting members could discuss and 
make a decision on the feasibility of developing and distributing model statements to 
commercial laboratories. None of the ACCLPP members expressed opposition to Dr. 
Brown's proposed approach. 
Ms. Mosby informed ACCLPP that she learned EPA has not developed an explicit definition 
of "green." However, green building is closely linked to EPA's pollution prevention acti"ities, 
including the reduction or elimination of waste at the source by modifying production 
processes and promoting the use of non-toxic or less toxic substances. Ms. Mosby 
conveyed that EPA's pollution prevention activities could be used as a mechanism to define 
"green." 
Ms. Mosby announced that EPA recently approved 15 of 80 applicants that subrnitted 
proposals in response to the new Community-Based Grant Program. The 15 awarded 
applicants are located throughout the country and will forge partnerships between national 
and community-based organizations to address infrastructure building, ordinance issues, 
outreach and education, and training. EPA expects to post a notice of approval of the 15 
awarded applicants on its web site by the end of September 2007. The total grant award is 
-$3.3 million. 
Dr. Friedman confirmed that both he and Ms. Mosby would follow-up on ATSM standards 
for laboratory projects and report their findings to ACCLPP at a future meeting. 
Dr. Brown reported that Ms. Valarie Johnson, an ACCLPP member, and Ms. Cassandra 
Archie, were scheduled to make a presentation on the previous day on educational selvices 
of lead poisoned children. Because the two speakers were unable to attend the meeting, 
this topic would be placed on ACCLPP's March 2008 agenda. 
Dr. Brown acknowledged the strong interest of CDC, ACCLPP and other national groups in 
developing recommendations for early childhood and early elementary education of lead 
poisoned children. She pointed out that CDC, ACCLPP and other organizations have made 
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The participants applauded Mr. Barry Brooks. Ms. Charlotte Cloud-Williams, MI. Joy 
Gulllk.en and Ms. Claudine Johnson, of lPPB, for providing outstanding administrative 
support and making logistical arrangements for the meeting. The next ACCL.PP meeting 
would be held on Marcn 18-19,2008 In Atlanta, Georgia. 
With no further di8cussion or business brought before ACCLPP, Dr. Rhoads adjourned the 
meeting at 11 :50 a.m. on September 19, 2007. 
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